Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy

Journal of Surgical Oncology

Volumn 113, Issue 5, 2016, Pages 477-484

  Kemeny, Nancy E ^a   Chou, Joanne F ^a   Boucher, Taryn M ^a   Capanu, Marinela ^a   DeMatteo, Ronald P ^a   Jarnagin, William R ^a   Allen, Peter J ^a   Fong, Yuman C ^a,b   Cercek, Andrea ^a   D'Angelica, Michael I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

adjuvant therapy; colorectal cancer; hepatic arterial infusion; liver metastases; survival

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HEPATIC ARTERIAL INFUSION; HUMAN; INFUSION; LIVER METASTASIS; LIVER RESECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SYSTEMIC CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; MORTALITY; SECONDARY; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; FLOXURIDINE; FLUOROURACIL; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; YOUNG ADULT;

EID: 84957554177     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24189     Document Type: Article

References (44)

1. Kopetz S, Chang GJ, Overman MJ, et al.,: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 4677-3683.
2. Fong Y, Fortner J, Sun RL, et al.,: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-321.
3. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al.,: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 4575-4580.
4. Saltz LB, Cox JV, Blanke C, et al.,: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 2000; 343: 905-914.
5. de Gramont A, Figer A, Seymour M, et al.,: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
6. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al.,: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
7. Cunningham D, Humblet Y, Siena S, et al.,: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
8. Amado RG, Wolf M, Peeters M, et al.,: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
9. Frankel TL, D'Angelica MI,: Hepatic resection for colorectal metastases. J Surg Oncol 2014; 109: 2-7.
10. Andres A, Majno PE, Morel P, et al.,: Improved long-term outcome of surgery for advanced colorectal liver metastases: Reasons and implications for management on the basis of severity score. Ann Surg Oncol 2008; 15: 134-143.
11. Fong Y, Cohen AM, Fortner JG, et al.,: Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946.
12. de Jong MC, Pulitano C, Ribero D, et al.,: Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: An international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250: 440-448.
13. Ackerman NB,: The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 1974; 75: 589-596.
14. Ensminger WD, Gyves JW,: Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 1983; 10: 176-182.
15. Kemeny N, Huang Y, Cohen AM, et al.,: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-2048.
16. Kemeny MM, Adak S, Gray B, et al.,: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-An intergroup study. J Clin Oncol 2002; 20: 1499-1505.
17. Lygidakis NJ, Sgourakis G, Vlachos L, et al.,: Metastatic liver disease of colorectal origin: The value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 2001; 48: 1685-1691.
18. Lorenz M, Müller HH, Schramm H, et al.,: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German cooperative on liver metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228: 756-762.
19. Kemeny NE, Gonen M,: Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352: 734-735.
20. Kemeny N, Jarnagin W, Gonen M, et al.,: Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol 2003; 21: 3303-3309.
21. Kemeny N, Capanu M, D'Angelica M, et al.,: Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil, and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 2009; 20: 1236-1241.
22. Kemeny NE, Jarnagin WR, Capanu M, et al.,: Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol 2010; 29: 884-889.
23. Kemeny N,: Is hepatic infusion of chemotherapy effective treatment for liver metastases ? Yes! Important Adv Oncol 1992; 207-227.
24. Nordlinger B, Guiguet M, Baillant JC, et al.,: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-1262.
25. Kemeny N, Seiter K, Niedzwiecki D, et al.,: A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69: 327-333.
26. Yaeger R, Cowell E, Gewirtz A, et al.,: RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer 2015; 121: 1195-1203.
27. Janakiraman M, Vakiani E, Zeng Z, et al.,: Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010; 70: 5901-5911.
28. Therneau T, Grambsch P,: Modeling survival data. New York: Springer; 2000.
29. Collett D,: Modeling survival data in medical research, 2nd edition. London, United Kingdom: Chapman and Hall; 2003.
30. Are C, Gonen M, Zazzali K, et al.,: The impact of margins on outcome after hepatic resection for colorectal metastases. Ann Surg 2007; 246: 295-300.
31. Siegel R, DeSantis C, Jemal A,: Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104-117.
32. Jamison RL, Donohue JH, Nagorney DM, et al.,: Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997; 465: 505-510.
33. Scheele J, Stang R, Altendorf-Hofmann A, et al.,: Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
34. Minagawa M, Makucchi M, Torzilli G, et al.,: Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: Long-term results. Ann Surg 2000; 231: 487-499.
35. Hamady ZZR, Cameron IC, Wyatt J, et al.,: Resection margin in patients undergoing hepatectomy for colorectal liver metastases: A critical appraisal of the 1cm rule. Eur J Surg Oncol 2006; 32: 557-563.
36. Giuliante F, Ardito F, Vellone M, et al.,: Role of the surgeon as a variable in long-term survival after liver resection for colorectal metastases. J Surg Oncol 2009; 100: 538-545.
37. Nordlinger B, Sorbye H, Glimelius B, et al.,: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomized control, phase 3 trial. Lancet Oncol 2013; 14: 1208-1215.
38. Abbas S, Lam V, Hollands M,: Ten-year survival after liver resection for colorectal metastases: Systematic review and meta-analysis. ISRN Oncol 2011; Article ID 763245:1-11 2011.
39. Vigano L, Capussotti L, Lapointe R, et al.,: Early recurrence after liver resection for colorectal metastases: Risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol 2014; 21: 1276-1286.
40. Gillams A, Khan Z, Osborn P, et al.,: Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases. Cardiovasc Intervent Radiol 2013; 36: 724-730.
41. Diaz-Rubio E, Gomez-Espana A, Massuti B, et al.,: Role of KRAS status is patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: A TTD group cooperative study. PLoS ONE 2012; 7: DOI: 10.1371/journal.pone.0047345
42. Loupakis F, Cremolini C, Masi G, et al.,: Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-1618.
43. Douillard JY, Siena S, Cassidy J, et al.,: Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 1346-1355.
44. Butte JM, Gonen MA, Allen PJ, et al.,: Recurrence after partial hepatectomy for metastatic colorectal cancer: Potentially curative role of salvage repeat resection. Ann Surg Oncol 2015; 22: 2761-2771.